The Harvard Medical School Department of Dermatology T32 training grant has been active for more than 45 years, and over that period of time has trained many postdoctoral fellows who have become national leaders in dermatology. Dr. Thomas Kupper has served as Principal Investigator since 2000. There are three Harvard-appointing Dermatology departments: the Beth Israel Deaconess Hospital, Brigham and Women's Hospital, and Massachusetts General Hospital. An executive committee comprised of the chairs of these departments oversees the Harvard combined residency program, and provides advice and counsel to Dr. Kupper with regard to the T32 grant. The training grant has two overarching goals. The first is to identify, recruit, and support promising dermatologist physician scientists interested in a career in biomedical research. While such candidates most often come from Harvard's Dermatology Residency program, trainees from other dermatology residencies are eligible as well. The second goal is to support the development of outstanding PhD scientists who are interested in a research career in investigative dermatology and related fields. Considering the past decade of the training grant, all 30 of our trainees continue to be involved with biomedical research, whether in academic medicine or biotechnology/pharmaceutical companies. This group of 30 trainees has authored 173 peer-reviewed manuscripts over the past decade, with a mean impact factor of 7.9. Over the past decade, T32 graduates have successfully competed for extramural funding as PI's, including National Institutes of Health K23, K12, K08, and DP5 awards (from the Office of the NIH Director); applications for K99/R00 and K08 grants are pending. For the next funding cycle, we have retained our External Advisory Board consisting of eminent academic dermatologists and scientists who will assist with choosing candidates and evaluating progress. It remains our conviction that Training Grant support for biomedical scientist postdoctoral fellows interested in skin disease research has never been more critical to their careers, and by extension, the long-term survival of academic investigative dermatology.